Astellas Pharma Global Development
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$111.8M
Doctors Paid
1,437
Transactions
18,207
2024 Total
$8.8M
Payment Breakdown by Category
Research$108.3M (96.9%)
Consulting$3.1M (2.8%)
Travel$206,021 (0.2%)
Food & Beverage$90,542 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $108.3M | 15,694 | 96.9% |
| Consulting Fee | $3.1M | 767 | 2.8% |
| Travel and Lodging | $206,021 | 261 | 0.2% |
| Food and Beverage | $90,542 | 1,431 | 0.1% |
| Honoraria | $19,295 | 4 | 0.0% |
| Education | $2,566 | 50 | 0.0% |
Payments by Type
Research
$108.3M
15,694 transactions
General
$3.5M
2,513 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Maligt Solid Tumors (EV-202) | $6.4M | 0 | 341 |
| Observational Disease Registry of Patients Treated With Systemic Mold-Active Triazoles | $5.9M | 7 | 316 |
| OBSERVATIONAL DISEASE REGISTRY OF PATIENTS TREATED WITH SYSTEMIC MOLD-ACTIVE TRIAZOLES | $5.6M | 0 | 82 |
| An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | $5.3M | 0 | 1,030 |
| A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | $3.8M | 1 | 356 |
| A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects with OAB | $3.6M | 0 | 101 |
| A MULTINATIONAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS ANDROGEN DEPRIVATION THERAPY ADT VERSUS PLACEBO PLUS ADT IN PATIENTS WITH METASTATIC HORMONE SENSITIVE PROSTATE CANCER MHSPC | $3.3M | 8 | 585 |
| A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms | $2.8M | 0 | 750 |
| A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3ITD AML | $1.9M | 0 | 172 |
| A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With Overactive Bladder (OAB) Symptoms While Taking the Alpha Blocker Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) | $1.9M | 0 | 129 |
| A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With Overactive Bladder OAB Symptoms While Taking the Alpha Blocker Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms LUTS Due to Benign Prostatic Hyperplasia BPH | $1.9M | 6 | 476 |
| A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy | $1.7M | 0 | 723 |
| An Open-Label Extension (OLE) Phase 3 Trial to Assess the Safety of Intravitreal Administration of Avacincaptad Pegol (Complement C5 Inhibitor) in Patients with Geographic Atrophy who Previously Completed Phase 3 Study ISEE2008 (GATHER2) | $1.5M | 0 | 200 |
| A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance (ENACT) | $1.5M | 13 | 254 |
| A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | $1.5M | 0 | 660 |
| An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) | $1.4M | 5 | 344 |
| AN OPEN-LABEL, RANDOMIZED PHASE 3 STUDY TO EVALUATE ENFORTUMAB VEDOTIN VS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER (EV-301) | $1.4M | 3 | 190 |
| Randomized Trial of Gilteritinib vs Midostaurin in FL T3 Mutated Acute Myeloid Leukemia | $1.4M | 0 | 129 |
| A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy ADT Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer mHSPC | $1.3M | 0 | 221 |
| A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL OF THE FLT3 INHIBITOR GILTERITINIB ADMINISTERED AS MAINTENANCE THERAPY FOLLOWING ALLOGENEIC TRANSPLANT FOR PATIENTS WITH FLT3/ITD AML | $1.2M | 0 | 131 |
| A Phase 1 Study of ASP2215 in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia | $1.2M | 0 | 166 |
| ASTAGRAF XL TO UNDERSTAND THE IMPACT OF IMMUNOSUPPRESSION ON DE NOVO DSA DEVELOPMENT AND CHRONIC IMMUNE ACTIVATION IN KIDNEY TRANSPLANTATION | $1.2M | 4 | 250 |
| A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | $1.1M | 11 | 319 |
| A Randomized Study of Enzalutamide in Patients with Localized Prostate Cancer Undergoing Active Surveillance | $1.1M | 0 | 261 |
| A PHASE 2 OPEN-LABEL EXTENSION STUDY FOR SUBJECTS WITH PROSTATE CANCER WHO PREVIOUSLY PARTICIPATED IN AN ENZALUTAMIDE CLINICAL STUDY | $1.1M | 0 | 172 |
| A Multinational Phase 3 Randomized Double-blind Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | $995,640 | 10 | 371 |
| A Phase I/II Study of Azacitidine, Venetoclax, and Gilteritinib for Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome with an Activating FLT3 Mutation | $883,769 | 0 | 15 |
| A Prospective Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC) in the United States | $814,171 | 5 | 151 |
| A Multicenter, Open-label Treatment Protocol of Gilteritinib ASP2215 in Patients With FMS-like Tyrosine Kinase 3 FLT3 Mutated Relapsed or Refractory Acute Myeloid Leukemia AML or FLT3-Mutated AML in Complete Remission CR With Minimal Residual Disease MRD | $805,550 | 0 | 135 |
| To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody DSA Formation and the Development of Immune Activation IA in de Novo Kidney Transplant Recipients | $800,631 | 0 | 111 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2019 |
|---|---|---|---|---|
| Alexander Ford, Md, MD | Cardiovascular Disease | Los Angeles, CA | $143,310 | $0 |
| Dr. Neal Shore, Dr, DR | Urology | Myrtle Beach, SC | $110,461 | $0 |
| Chun Kim, Md, MD | Nuclear Medicine | New York, NY | $97,210 | $0 |
| Dr. Brian Barr, Md, MD | Cardiovascular Disease | Baltimore, MD | $94,800 | $0 |
| Dr. Steve Freedland, M.d, M.D | Urology | West Hollywood, CA | $92,397 | $0 |
| Mr. George Oliveira, M.d, M.D | Diagnostic Radiology | Miami, FL | $90,610 | $0 |
| David Staskin, Md, MD | Urology | Brighton, MA | $87,748 | $0 |
| Marlyn Goldberg, M.d, M.D | Ophthalmology | Elmhurst, IL | $74,925 | $0 |
| Dr. Daniel Petrylak, M.d, M.D | Hematology & Oncology | New Haven, CT | $70,715 | $0 |
| Andrew Armstrong, Md, MD | Medical Oncology | Durham, NC | $70,695 | $0 |
| Dr. Nisha Sainani, M.d, M.D | Body Imaging | Boston, MA | $64,000 | $0 |
| Yingbing Wang, Md, MD | Nuclear Medicine | San Francisco, CA | $63,640 | $0 |
| Christopher Evans, M.d, M.D | Urology | Reno, NV | $62,644 | $0 |
| Dr. James Scott, Md, MD | Nuclear Medicine | Boston, MA | $62,080 | $0 |
| Alexander Perl, Md, MD | Medical Oncology | Philadelphia, PA | $60,660 | $0 |
| Dr. Russell Szmulewitz, M.d, M.D | Hematology & Oncology | Chicago, IL | $59,973 | $0 |
| Amer Zeidan | Hematology & Oncology | New Haven, CT | $56,534 | $0 |
| Cheryl Sadow, Md, MD | Body Imaging | Boston, MA | $55,400 | $0 |
| Robert Ellison, M.d, M.D | Public Health & General Preventive Medicine | Roxbury, MA | $54,675 | $0 |
| Dr. Eleonora Lad, Md, Phd, MD, PHD | Specialist | Durham, NC | $52,050 | $0 |
| Dr. Dilraj Grewal, Md, MD | Ophthalmology | Chicago, IL | $51,750 | $0 |
| Antonio Arrieta, M.d, M.D | Pediatric Infectious Diseases | Orange, CA | $49,351 | $0 |
| Dr. Michael Allingham, M.d., Ph.d, M.D., PH.D | Retina Specialist | Durham, NC | $49,350 | $0 |
| Gregg Miller, M.d, M.D | Diagnostic Radiology | Boston, MA | $48,170 | $0 |
| Priyatham Mettu, M.d, M.D | Ophthalmology | Durham, NC | $47,700 | $0 |
Ad
Top Products
- CRESEMBA $15.7M
- Padcev $13.3M
Associated Products (27)
- CRESEMBA $17.5M
- XOSPATA $16.3M
- Xtandi $13.7M
- Cresemba $6.4M
- Mirabegron $6.2M
- Xospata $5.7M
- ENZALUTAMIDE $4.8M
- Enzalutamide $4.7M
- MIRABEGRON $2.9M
- ASTAGRAF XL $2.2M
- TACROLIMUS EXTENDED RELEASE CAPSULES $961,014
- REGADENOSON $917,193
- Regadenoson $824,025
- Micafungin $623,864
- Tacrolimus Oral $532,855
- Vyloy $352,877
- TARCEVA $220,432
- TACROLIMUS ORAL $202,748
- Astagraf XL $163,293
- Prograf $143,975
- ERLOTINIB $103,258
- MICAFUNGIN $61,510
- Amphotericin B $56,609
- Mycamine $34,915
- AMPHOTERICIN B $33,675
- Solifenacin $23,632
- PROGRAF $12,160
Payment Categories
- Food & Beverage $90,542
- Consulting $3.1M
- Travel & Lodging $206,021
- Research $108.3M
About Astellas Pharma Global Development
Astellas Pharma Global Development has made $111.8M in payments to 1,437 healthcare providers, recorded across 18,207 transactions in the CMS Open Payments database. In 2024, the company paid $8.8M. The top product by payment volume is CRESEMBA ($15.7M).
Payments were distributed across 84 medical specialties. The top specialty by payment amount is Urology ($984,688 to 200 doctors).
Payment categories include: Food & Beverage ($90,542), Consulting ($3.1M), Research ($108.3M), Travel & Lodging ($206,021).
Astellas Pharma Global Development is associated with 27 products in the CMS Open Payments database, including CRESEMBA, XOSPATA, and Xtandi.